Tells the body to release its own growth hormone — studied for metabolism and body fat. Below: what Tesamorelin is, what it does in plain terms, and the published studies — for laboratory research use only.
- Class
- GHRH analog
- Published studies cited
- 8
- Literature span
- 2009–2024
What Tesamorelin is
Tesamorelin is a lab-made copy of a natural 'releasing hormone' (GHRH) that tells the body to produce growth hormone. It is supplied as an analytical-grade reference material for laboratory research.
Where it comes from
Tesamorelin is a stabilized analog of human growth-hormone-releasing hormone (GHRH). Chemically it is the full-length GHRH(1-44) sequence with a small stabilizing group (a hexenoyl modification) added to its N-terminal end, which protects it from rapid breakdown so it can act longer than the native hormone. Developed by the company Theratechnologies and characterized in the late 2000s, it went on to be studied in a series of clinical trials — most prominently in people with HIV-associated fat redistribution — and became a clinically approved growth-hormone-releasing analog.
What it does — in plain terms
Your brain uses GHRH as a 'please release some growth hormone' message to the pituitary gland. Tesamorelin imitates that message rather than adding growth hormone directly. So research studies how gently nudging the body's own growth-hormone system affects metabolism — it has been examined in clinical settings especially around a specific type of deep abdominal fat.
How it works
Like the body's own GHRH, tesamorelin carries a single message to the pituitary gland: release a pulse of growth hormone. It binds the GHRH receptor and prompts the pituitary to secrete the body's own growth hormone, rather than supplying growth hormone from outside. The engineered N-terminal cap slows the enzymes that would otherwise degrade natural GHRH within minutes, so tesamorelin drives the receptor for longer.
Downstream, that pulse of growth hormone raises IGF-1 and, in the clinical research, changed where the body stores fat. Tesamorelin's most-studied effect is a reduction of visceral adipose tissue — the deep abdominal fat packed around the organs — in people with HIV-associated fat redistribution (lipodystrophy). Researchers are careful to distinguish this deep visceral fat from fat just under the skin; the trials specifically tracked the visceral compartment.
Because it works by nudging the body's own axis, tesamorelin tends to preserve the natural pulsing pattern of growth-hormone release, and its effects reverse when it is stopped. Later research also examined its impact on liver fat (NAFLD) in the same populations, extending the metabolic questions beyond visceral fat alone.
What the research shows
Tesamorelin is one of the better-documented compounds in this group: it has been through genuine human clinical trials, and it reached regulatory approval as a growth-hormone-releasing analog. The important caveat is scope — most of that clinical evidence sits in a specific population (HIV-associated lipodystrophy) and centers on visceral fat, IGF-1, and liver fat, rather than broad metabolic benefits in the general population. With that framing, here is what the key published work reports.
- Research overview, 2012 — surveyed tesamorelin as a growth-hormone-releasing hormone analog, summarizing its mechanism and its study in HIV-associated visceral fat accumulation.
- AIDS, 2024 — examined tesamorelin in people living with HIV, contributing clinical data on how the GHRH analog affects growth-hormone-related metabolic markers.
- Nature Reviews Drug Discovery, 2011 — profiled tesamorelin as a growth-hormone-releasing analog, summarizing its development and approved use in HIV-associated lipodystrophy.
- BETA, 2010 — gave a research update on tesamorelin and its study in HIV-associated fat accumulation.
- Drugs, 2011 — reviewed tesamorelin in HIV-associated lipodystrophy, summarizing trial evidence for its effect on visceral abdominal fat.
- The Annals of Pharmacotherapy, 2012 — reviewed the growth-hormone-releasing analog tesamorelin and its studied role in reducing excess visceral fat in HIV-associated lipodystrophy.
- Expert Opinion on Investigational Drugs, 2009 — described tesamorelin as a growth-hormone-releasing analog in development, covering its early mechanism and clinical rationale.
- JCI Insight, 2020 — examined tesamorelin and liver fat (NAFLD) in people living with HIV, extending its study from visceral fat to the liver.
What Tesamorelin is studied for
Growth-hormone release via GHRH. Tesamorelin binds the GHRH receptor so the pituitary secretes the body's own growth hormone; the engineered N-terminal cap lets it drive that receptor longer than natural GHRH.
Visceral fat in HIV-associated lipodystrophy. Its most-studied effect: in clinical trials, tesamorelin reduced visceral adipose tissue — the deep abdominal fat around the organs — in people with HIV-associated fat redistribution.
IGF-1 and metabolic markers. Because growth hormone raises IGF-1, studies tracked IGF-1 alongside glucose and lipid measures to gauge how the axis responds.
Liver fat (NAFLD). Later research extended the question to fat in the liver, examining tesamorelin's effect on hepatic fat in the same HIV populations.
Storage & handling
As a lyophilized powder, tesamorelin reference material is most stable kept cold and dark — refrigerated for short-term storage, frozen for longer holds. Once reconstituted with bacteriostatic water it should be refrigerated at roughly 2–8 °C, protected from light, and kept away from repeated freeze-thaw cycles, which are hard on peptides. Use the reconstitution reference below for the concentration math. Supplied for laboratory research use only.
Plain-language explanations describe what researchers study — not what any product does for a person, and not medical advice. Every material here is sold for laboratory research use only and is not for human or animal use.
Studies cited
- Tesamorelin — overview (, 2012)
- Tesamorelin in HIV patients — clinical study (AIDS (London, England), 2024)
- Tesamorelin — drug profile (Nature reviews. Drug discovery, 2011)
- Tesamorelin — research update (BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2010)
- Tesamorelin and HIV-associated lipodystrophy — review (Drugs, 2011)
- Tesamorelin growth-hormone analogue — HIV lipodystrophy (The Annals of pharmacotherapy, 2012)
- Tesamorelin — growth-hormone-releasing analogue (Expert opinion on investigational drugs, 2009)
- Tesamorelin and fatty liver in HIV (NAFLD) (JCI insight, 2020)
Questions
What is tesamorelin?
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor to prompt the pituitary to release the body's own growth hormone. It is supplied here as an analytical-grade reference material for laboratory research use only.
How is tesamorelin different from taking growth hormone?
Tesamorelin works one step upstream. Instead of supplying growth hormone directly, it stimulates the GHRH receptor so the pituitary makes its own — which tends to preserve the body's natural pulsing rhythm of release.
What has tesamorelin been studied for?
Its most-studied effect in clinical trials is reducing visceral adipose tissue — deep abdominal fat — in people with HIV-associated fat redistribution (lipodystrophy). Later studies also examined its effect on liver fat and on IGF-1 and other metabolic markers.
Is tesamorelin supported by human clinical trials?
Yes, more than most compounds in this group — it has been through human trials and reached regulatory approval as a GHRH analog. The main caveat is scope: that evidence is concentrated in HIV-associated lipodystrophy and specific metabolic readouts, not broad benefits in the general population.
Is this product for human use?
No. It is sold strictly as a reference material for laboratory research use only — not for human or veterinary use, and not as a drug or supplement.
For laboratory research and educational purposes only. Not medical advice. The materials discussed are not for human or animal consumption and have not been evaluated by the FDA.